Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
Use of the BreathID to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Patients With Cirrhosis in Need of Liver Transplantation
Sponsor: Hadassah Medical Organization
Terminated
Company restructured and protocol restructured. Resubmitted with IDE approval under new company name-Exalenz
Other terminated trials from Hadassah Medical Organization
Listed as NCT00375011, this observational or N/A phase trial focuses on Cirrhosis and remains terminated or withdrawn. Sponsored by Hadassah Medical Organization, it has been updated 12 times since 2008, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2023 — Jul 2024 [monthly]
Terminated
-
Dec 2021 — Jan 2023 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
▶ Show 7 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated
-
Aug 2018 — Nov 2020 [monthly]
Terminated
-
Jun 2018 — Aug 2018 [monthly]
Terminated
-
May 2018 — Jun 2018 [monthly]
Terminated
-
Apr 2018 — May 2018 [monthly]
Terminated
Phase: PHASE3 → None
-
Aug 2017 — Apr 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE3
First recorded
Sep 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hadassah Medical Organization
- Meridian Bioscience, Inc.
- US Department of Veterans Affairs
- Virginia Commonwealth University
For direct contact, visit the study record on ClinicalTrials.gov .